197 results about "Selectin" patented technology

Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.

The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

Carboxymethylgalactose derivatives represented by general formula (1);and salts thereof, which exhibit reactivity to selectins and are useful as inhibitors against selectin-related diseases such as various inflammations and cancerous metastasis; In said formula, R is a group rep resented by formula (1a), (1b) or (1c).

An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal alpha 2->3 sialylation and internal alpha 1->3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).

A conjugate includes at least one target-seeking unit, which specifically binds to receptors on the surface of endothelial cells, and at least one effector unit which is coupled to the unit by a linker. The effector unit exhibits at least one signal unit and optionally at least one therapeutic active substance. The target-seeking unit includes a lectin or a fragment or derivative thereof, wherein the lectin is not L-selectin and the signal unit includes a lanthanide ion.

The present invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist.

Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids).

The present invention relates to an antigenic fusionprotein, which carries multiple Galα1,3Gal epitopes. The fusion protein according to the invention may also be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1, and a part, which exhibits immunoglobulin properties, such as the Fc part of IgG. The fusionprotein according to the invention is preferably used as an absorber to prevent a hyperacute rejection of a xenotransplant, such as a pig tissue or organ transplanted into a human patient. In addition, the invention relates to a method for the prevention of hyperacute rejection reaction in a patient who is to receive a xenotransplant.

The invention provides a simple and convenient Agrobacterium Tumefacies dual carrier containing double T-DNA structural regions, and a method of using the carrier system to cultivate transgenic rice without resistance selection label. With the help of the principle of co-conversion mediated by root nodule Agrobacterium Tumefacies, the system contains two separate T-DNA structural sections, where the first T-DNA region contains antibiotic resistance selection label gene and the second one contains a universal polyclonal site able to be arbitrarily inserted with destination gene. The double-T-DNA carrier has small molecular weight, easy to clone and after the destination gene and necessary regulation and control series are cloned in the T-DNA region containing the polyclonal site, it realizes rice co-conversion; by selfing, it selects transgenic individual with destination gene but without selectin label gene from the self-bred progeny, thus eliminating the negative effect on transgenic plant commercialized production, etc, possibly caused by selection label gene.

Compositions containing one or more peptido-mimetics or modified peptido-mimetics of a carbohydrate ligand of an adhesion molecule in a physiologically acceptable carrier are useful for methods of reducing metastasis in a mammal and for inhibiting inflammatory response in a mammal. Particularly useful are embodiments in which the ligand is a Lewis antigen and/or the adhesion molecule is a selectin, e.g., E-selectin. Methods are disclosed for identifying peptido-mimetics of carbohydrate ligands, which may be involved in binding of tumor cells to other cells, such as endothelial cells.

A hemostatic composition which comprises at least one procoagulant metal ion, such as silver (I) or mercury (II), and at least one procoagulant biopolymer, such as collagen, thrombin, prothrombin, fibrin, fibrinogen, heparinase, Factor VIIa, Factor VIII, Factor IXa, Factor Xa, Factor XII, von Willebrand Factor, a selectin, a procoagulant venom, a plasminogen activator inhibitor, glycoprotein IIb-IIIa, a protease, or plasma. The composition in the form of a paste, dough, glue, liquid, lyophilized powder or foam, may be provided, for application to a wound. A hemostatic device is also described which comprises a hemostatic composition as described above. The device may be in the form of, for example, a plug, bandage, gauze, cloth, tampon, membrane or sponge. Methods are also provided for prophylaxis or treatment of bleeding at a site by application to the site of the composition or device as described.

With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.

The invention relates to an amphiphilic polysaccharide derivative carrier for targeting tumor new blood vessels. According to the derivative, a polysaccharide skeleton is coupled with functional polypeptide targeting E-selectin by virtue of a disulfide bond to ensure that polysaccharide has amphipathy, and is assembled into nano particles for targeting the tumor new blood vessels after carrying an antitumor drug or a tumor new blood vessel inhibitor in an aqueous medium. The nano particles deliver medicines to the tumor new blood vessels in an active targeting manner by virtue of the high affinity between the functional polypeptide targeting the E-selectin and the E-selectin on the surface of the tumor new blood vessels, then a disulfide bond connecting arm can be specifically degraded by a strong reducing environment in endothelial cells of the tumor new blood vessels to cause that the functional polypeptide targeting the E-selectin is separated from polysaccharide, and the medicines are quickly released to treatment target points, so that the concentration of free medicines at tumor new blood vessel parts can be significantly improved and the antitumor curative effect is enhanced. An auxiliary material can be used as a carrier for water-insoluble, indissolvable or amphiphilic antitumor drugs and the tumor new blood vessel inhibitor, and is administrated by injecting into blood vessels or muscles, or is administrated orally or externally. The amphiphilic polysaccharide derivative carrier provided by the invention is simple in preparation method, mature in process and suitable for large-scale production.

Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Ser, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P- selectin expression in vivo. Therefore, theinvention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P- selectin antagonist. The formulas are shown in the decription.